Compare PRSO & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRSO | HIND |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | 18 |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 15.2M |
| IPO Year | 2000 | 2016 |
| Metric | PRSO | HIND |
|---|---|---|
| Price | $0.69 | $2.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 321.7K | 11.8K |
| Earning Date | 05-11-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $14,573,000.00 | N/A |
| Revenue This Year | $18.48 | N/A |
| Revenue Next Year | $53.57 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.99 | N/A |
| 52 Week Low | $0.68 | $1.75 |
| 52 Week High | $2.37 | $12.87 |
| Indicator | PRSO | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 33.54 | 39.79 |
| Support Level | N/A | $1.99 |
| Resistance Level | $0.94 | $2.33 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 12.21 | 0.00 |
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.